%0 Journal Article
%T Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review.
%A Bhoopalan SV
%A Wlodarski M
%A Reiss U
%A Triplett B
%A Sharma A
%J Pediatr Blood Cancer
%V 68
%N 10
%D Oct 2021
%M 34086408
%F 3.838
%R 10.1002/pbc.29177
%X <B>BACKGROUND: </B>Bone marrow failure in dyskeratosis congenita (DKC) is progressive, and allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment. However, outcomes after HCT are suboptimal because of mucosal, vascular, pulmonary, and hepatic fragility, which can be exacerbated by chemotherapy conditioning and graft-versus-host disease (GVHD). These toxicities can be mitigated by reducing the intensity of the conditioning regimen.<BR><B>METHODS: </B>We performed a retrospective analysis on pediatric patients with DKC who underwent HCT at our institution between 2008 and 2019.<BR><B>RESULTS: </B>We identified nine patients (median age, 5.7 years) who underwent HCT with a fludarabine-based reduced-intensity conditioning (RIC) regimen. GVHD prophylaxis consisted of tacrolimus plus mycophenolate mofetil (MMF) (n  =  8), tacrolimus/pentostatin (n  =  1), or cyclosporine/MMF (n  =  1). The median time to neutrophil engraftment was 19 days (range, 13-26 days), and the median time to platelet engraftment was 18 days (range, 17-43 days). Lung function, as measured by spirometry in six patients, remained stable during post-HCT observation. Six patients (67%) remain alive, with a median follow-up of 73.5 months.<BR><B>CONCLUSIONS: </B>Because of toxicity after myeloablative conditioning, RIC is becoming standard for HCT in DKC. These results suggest that RIC regimen is feasible and safe for patients with DKC and does not accelerate pulmonary damage in the short-to-medium term after HCT.